News

Standing up in public for a broader conception of value in healthcare.

1-8 of 72 News

viewpoint 7/12/17

On the Health Affairs Blog: Sachs Provides an Overview of FDA User Fee Reauthorization Bill Rachel Sachs reviews some of the key provisions of the House of Representative's just-released FDA user fee authorization bill, detailing the recent amendments and what's at stake. READ MORE

viewpoint 6/20/17

On the Health Affairs Blog: Sachs Summarizes Recent HELP Committee Meeting: The Elephant in the Room Rachel Sachs provides a summary of the recent Senate Health, Education, Labor & Pensions (HELP) Committee meeting, organized to focus on how the drug delivery system affects what patients pay. Although the meeting began with a focus on pricing, it soon shifted to a partisan rebuke of the planned ACA repeal. READ MORE

viewpoint 6/19/17

On the Health Affairs Blog: Lietzan Examines SCOTUS Ruling on Biosimilars Erica Lietzan breaks down the recent Supreme Court Sandoz v. Amgen ruling, providing perspective on how the ruling will affect the pathway for approval of biosimilars. READ MORE

viewpoint 6/19/17

IVI's Lakdawalla in WSJ: Look to Major League Baseball for Drug Pricing Insight In a new coauthored commentary appearing in The Wall Street Journal, IVI Executive Director Darius Lakdawalla turns to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. READ MORE

research 6/14/17

IVI Releases Protocol for Report on Cost Effectiveness Analysis in Health Care IVI released the research protocol for its first project, which examines the quality of evidence and methods used in cost effectiveness analysis in healthcare. READ MORE

viewpoint 6/13/17

On the Health Affairs Blog: Sood, Shih, Van Nuys and Goldman's Study Details the Flow of Funds in Pharma's Distribution System Neeraj Sood, Tiffany Shih, Karen Van Nuys and Dana Goldman discuss the findings of their new study, examining the flow of funds in the pharmaceutical distribution system. READ MORE

press 6/13/17

IVI Highlighted in Article on Value Assessment in Oncology Treatments The IVI was recently highlighted in a article focused on value assessment in oncology treatments, emphasizing the potentially tremendous impact that value assessments will have on future patient reimbursement decisions. READ MORE

viewpoint 6/08/17

Jena and Goldman Discuss the Challenges of Value-Based Pricing in STAT News In a new commentary for STAT News, Anupam Jena (part of IVI's scientific advisory group) and Dana Goldman discuss the advantages of value-based pricing, pointing out several of the key challenges that complicate the application of health technology assessments. READ MORE